Dolutegravir and Empagliflozin Interaction
Drug interaction information between Dolutegravir and Empagliflozin.
Dolutegravir and Empagliflozin have a documented moderate interaction in FDA labeling.
FDA drug labeling documents a moderate-severity interaction between Dolutegravir and Empagliflozin. This page displays the available source-record category and label text. The category is not an individual risk estimate or medication-combination direction.
How They Interact
Dolutegravir blocks the kidneys from removing metformin from the body. This can cause metformin levels to rise, which increases the risk of a serious condition called lactic acidosis.
FDA Label Information
Drugs that Reduce Metformin Clearance Clinical Impact Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3) ] .
Dolutegravir Also Interacts With
- Dofetilide major
- Empagliflozin/Linagliptin moderate
- Ertugliflozin moderate
- Linagliptin moderate
- Metformin/Empagliflozin moderate
Empagliflozin Also Interacts With
- Metformin moderate
- Ranolazine moderate
- Metformin/Empagliflozin moderate
- Cimetidine moderate
- Topiramate minor
Frequently Asked Questions
What SPL severity band is on file for Dolutegravir + Empagliflozin?
Compiled FDA labeling labels this pair moderate. That is a source-record field, not an individual medication-combination decision.
Which drug in this pair has the larger labeled-interaction portfolio?
Dolutegravir has 28 labeled pairs on file vs Empagliflozin's 10. In the moderate band specifically: Dolutegravir has 6 (also Empagliflozin/Linagliptin, Ertugliflozin, Linagliptin, Metformin/Empagliflozin); Empagliflozin has 5 (also Metformin, Ranolazine, Metformin/Empagliflozin, Cimetidine).
What mechanism field is on file for Dolutegravir and Empagliflozin?
Dolutegravir blocks the kidneys from removing metformin from the body. This can cause metformin levels to rise, which increases the risk of a serious condition called lactic acidosis.
Dolutegravir carries more major-labeled pairs than Empagliflozin
SPL source-record counts only. This page's band is moderate · classes on file: Dolutegravir (Integrase Strand Transfer Inhibitor); Empagliflozin (SGLT2 Inhibitor).
Dolutegravir has 1 major-labeled pair vs Empagliflozin's 0. This page itself is in the moderate band, not the major band.
1 major · 6 moderate · 21 minor · 28 total
- Other moderate peers for Dolutegravir
- Empagliflozin/Linagliptin
- Ertugliflozin
- Linagliptin
- Metformin/Empagliflozin
0 major · 5 moderate · 5 minor · 10 total
- Other moderate peers for Empagliflozin
- Metformin
- Ranolazine
- Metformin/Empagliflozin
- Cimetidine
Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. This registry does not provide individual medication-combination directions.
Read our methodology - how this data is sourced, computed, and verified.